• Osteoblast ECM1 Drives Anti-Androgen Resistance in Bone Meta

  2026-07-29

  This study reveals how osteoblast-derived ECM1, secreted in response to enzalutamide therapy, fosters anti-androgen resistance in bone metastatic prostate cancer by activating the ENO1-MAPK signaling cascade in tumor cells. The findings illuminate a non-cell-autonomous mechanism of resistance, emphasizing the tumor microenvironment’s pivotal role and identifying ECM1 and ENO1 as potential therapeutic targets.

• AMPK’s Dual Role in Autophagy: New Insights from Glucose Sta

  2026-07-29

  This article examines a paradigm-shifting study that redefines the role of AMPK in autophagy during energy stress. Contrary to the prevailing model, the paper demonstrates that AMPK inhibits, rather than promotes, autophagy initiation by suppressing ULK1 activity. These findings have significant implications for research on energy metabolism and the use of AMPK activators such as A-769662.

• G-15: G Protein-Coupled Estrogen Receptor Antagonist in Rese

  2026-07-28

  G-15 is a selective G protein-coupled estrogen receptor antagonist that empowers researchers to dissect GPR30-mediated estrogen signaling with unmatched specificity. This guide translates cutting-edge reference findings and real-world workflows into actionable protocols, troubleshooting, and advanced applications—maximizing the value of G-15 from APExBIO for cellular and in vivo studies.

• MLKL-Induced Lysosomal Permeabilization Drives Necroptosis v

  2026-07-28

  This study elucidates how MLKL polymerization triggers lysosomal membrane permeabilization (LMP), leading to the release of cathepsin B and subsequent necroptotic cell death. The findings clarify a critical mechanistic step in regulated necrosis and highlight the protective effect of cathepsin B inhibition in this pathway.

• Phenacetin in Applied Pharmacokinetics: Workflows & Troubles

  2026-07-27

  Phenacetin (N-(4-ethoxyphenyl)acetamide) is a gold-standard probe compound, enabling high-fidelity pharmacokinetic workflows in human-relevant models. This article offers actionable, evidence-based strategies for maximizing data quality with APExBIO’s high-purity Phenacetin, including protocol enhancements, troubleshooting, and translational insights.

• Targeting Cpt1a-Bcl-2 Interaction to Reverse Macrophage Apop

  2026-07-27

  This study uncovers how direct interaction between Cpt1a and Bcl-2 in lung macrophages drives apoptosis resistance and promotes fibrotic remodeling in pulmonary fibrosis. Targeting Bcl-2, including with the selective inhibitor ABT-199, restores apoptosis sensitivity and reduces fibrosis, providing mechanistic insight and translational potential for fibrosis research.

• SEMA3E Regulates Beige Adipocyte Thermogenesis via β-Catenin

  2026-07-26

  The reference study uncovers SEMA3E as a pivotal factor promoting beige adipocyte differentiation and thermogenic activity in mice through β-catenin signaling modulation. These findings provide mechanistic insights into adipose tissue plasticity and highlight new molecular targets for metabolic and inflammation research.

• EPZ-6438: EZH2 Inhibitor Workflows for Epigenetic Cancer Res

  2026-07-25

  Explore how EPZ-6438 from APExBIO empowers high-sensitivity, reproducible epigenetic assays targeting the polycomb repressive complex 2 (PRC2) pathway. From cervical cancer models to lymphoma and MRT, discover protocol enhancements, troubleshooting strategies, and the translational impact of this selective EZH2 inhibitor.

• Ac-YVAD-CMK: Precision Pyroptosis Inhibition in Kupffer Cell

  2026-07-24

  Ac-YVAD-CMK (N-Ac-Tyr-Val-Ala-Asp-CMK) enables targeted inhibition of Caspase-1, empowering researchers to dissect inflammatory responses and pyroptosis in liver models with unprecedented specificity. This guide translates the latest TMEM16F-Kupffer cell findings into executable workflows, practical troubleshooting, and advanced assay design.

• Toremifene in Breast Cancer: 20 Years of Endocrine Therapy I

  2026-07-24

  This review examines two decades of clinical evidence on toremifene, a selective estrogen receptor modulator, for hormone receptor–positive breast cancer. The paper highlights the evolution of endocrine therapy, the clinical impact of molecular profiling, and the nuances of personalized treatment strategies.

• Ceftazidime in Gram-Negative Infection Research Workflows

  2026-07-23

  Ceftazidime, a third-generation cephalosporin, is a cornerstone for modeling and combating Gram-negative bacterial infections, notably Pseudomonas aeruginosa, due to its robust β-lactamase resistance. This article translates genomic surveillance insights and advanced assay protocols into actionable guidance for maximizing research productivity and overcoming resistance challenges.

• Tacrolimus (FK506): Applied Protocols for Immune Modulation

  2026-07-23

  Tacrolimus (FK506) offers unmatched precision for modulating T-cell activation and cytokine signaling in transplantation immunology and autoimmune disease models. This guide delivers practical workflows, comparative insights, and troubleshooting strategies to maximize reproducibility and data fidelity for investigators leveraging APExBIO’s rigorously formulated Tacrolimus.

• Doxycycline in Cancer and Antimicrobial Research Workflows

  2026-07-22

  Doxycycline’s dual role as a tetracycline antibiotic and a potent metalloproteinase inhibitor empowers both robust antimicrobial studies and advanced cancer research. Explore evidence-based workflows, troubleshooting strategies, and translational insights for maximizing experimental reproducibility with APExBIO’s high-purity Doxycycline (SKU BA1003).

• nor-NOHA Acetate: Optimized Arginase Inhibition in Cancer Wo

  2026-07-22

  nor-NOHA acetate enables precise, reversible control of arginine metabolism for dissecting immune and cancer cell function. This guide bridges the latest immunometabolic insights with actionable workflow enhancements, troubleshooting, and comparative protocol strategies for maximizing nor-NOHA’s research value.

• Rosiglitazone (Brl-49653): Beyond Adipogenesis—Innovations i

  2026-07-21

  Explore how Rosiglitazone (Brl-49653) advances metabolic disease research through PPARγ-driven adipogenesis and innovative assay design. This article uniquely bridges mechanistic insights with practical workflow optimization for type II diabetes and emerging metabolic applications.

411 records 7/28 page Previous Next First page 上5页 678910 下5页 Last page